Søren Weis Dahl

Chief Executive Officer at Deck Therapeutics, Inc.

58 year

Health Technology

Consumer Services

Profile

Søren Weis Dahl is currently the Chief Executive Officer & Director at Deck Therapeutics, Inc. He previously served as the Chief Executive Officer at Prophylix AS from 2015 to 2019 and as a Director at Pila Pharma AB in 2023.
Dr. Dahl holds an MBA from Copenhagen Business School, a doctorate from the Technical University of Denmark in 1997, and a graduate degree from the Technical University of Denmark in 1993.

Søren Weis Dahl active positions

Companies	Position	Start
Deck Therapeutics, Inc. Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020.	Chief Executive Officer	01/01/2014

All active positions of Søren Weis Dahl

Former positions of Søren Weis Dahl

Companies	Position	End
PILA PHARMA AB	Director/Board Member	01/04/2024
Prophylix AS Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.	Chief Executive Officer	01/01/2019

See the detail of Søren Weis Dahl's experience

Training of Søren Weis Dahl

Technical University of Denmark	Graduate Degree
Copenhagen Business School	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Søren Weis Dahl's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
PILA PHARMA AB	Health Technology

Private companies	2
Prophylix AS Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.	Health Technology
Deck Therapeutics, Inc. Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020.	Health Technology